Alectos Therapeutics Announces FDA Orphan Drug Designation for MK-8719: An Investigational …

VANCOUVER, BRITISH COLUMBIA, April 20, 2016 (GLOBE NEWSWIRE) — Alectos Therapeutics Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to OGA inhibitor MK-8719 for the treatment of progressive supranuclear palsy (PSP). Alectos also announced completion of a Phase 1 clinical trial in its ongoing collaboration with Merck, known as MSD outside the U.S. and Canada. This collaboration aims to develop agents that modulate the O-GlcNAcase (OGA) enzyme as a disease-modifying therapy for treatment of various neurodegenerative diseases. This follows the achievement of a previously undisclosed preclinical research milestone in 2012 under the same agreement.“We are gratified that our collaboration with the exceptional team at Merck has progressed to clinical testing of this novel disease-modifying therapeutic approach for patients affected by PSP and…


Link to Full Article: Alectos Therapeutics Announces FDA Orphan Drug Designation for MK-8719: An Investigational …